{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:53:57Z","timestamp":1794322437489,"version":"4.9.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12325-024-02856-3","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T08:01:50Z","timestamp":1713600110000},"page":"2486-2499","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8872-2678","authenticated-orcid":false,"given":"C\u00e9cile","family":"van Steen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Celico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Spaepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-3450","authenticated-orcid":false,"given":"Tim","family":"Hagenacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2571-3501","authenticated-orcid":false,"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6332-8650","authenticated-orcid":false,"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7909-9395","authenticated-orcid":false,"given":"A. Gordon","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2184-4865","authenticated-orcid":false,"given":"Danielle H.","family":"Bodicoat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7118-5845","authenticated-orcid":false,"given":"Maria","family":"de Francesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3226-5954","authenticated-orcid":false,"given":"Sergio","family":"Iannazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,20]]},"reference":[{"issue":"7","key":"2856_CR1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"key":"2856_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.553626","volume":"11","author":"P Szczudlik","year":"2020","unstructured":"Szczudlik P, et al. Determinants of quality of life in myasthenia gravis patients. Front Neurol. 2020;11: 553626.","journal-title":"Front Neurol"},{"issue":"5","key":"2856_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3109\/00207454.2015.1038712","volume":"126","author":"Y Yang","year":"2016","unstructured":"Yang Y, et al. Quality of life in 188 patients with myasthenia gravis in China. Int J Neurosci. 2016;126(5):455\u201362.","journal-title":"Int J Neurosci"},{"issue":"3","key":"2856_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"7","key":"2856_CR5","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, et al. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487\u20139.","journal-title":"Neurology"},{"key":"2856_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","author":"T Vu","year":"2022","unstructured":"Vu T, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022. https:\/\/doi.org\/10.1056\/EVIDoa2100066.","journal-title":"NEJM Evid"},{"key":"2856_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.791","author":"T Vu","year":"2022","unstructured":"Vu T, et al. Efficacy and safety of ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG study (P1\u20131.Virtual). Neurology. 2022. https:\/\/doi.org\/10.1212\/WNL.98.18_supplement.791.","journal-title":"Neurology"},{"issue":"2","key":"2856_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Mak. 2018;38(2):200\u201311.","journal-title":"Med Decis Mak"},{"issue":"6","key":"2856_CR9","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"key":"2856_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn RJ, et al. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841:769\u201372.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"2856_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/mus.21609","volume":"41","author":"TM Burns","year":"2010","unstructured":"Burns TM, et al. Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve. 2010;41(2):219\u201326.","journal-title":"Muscle Nerve"},{"issue":"12","key":"2856_CR12","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","volume":"30","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, et al. Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur J Neurol. 2023;30(12):3854\u201367.","journal-title":"Eur J Neurol"},{"key":"2856_CR13","doi-asserted-by":"crossref","unstructured":"Wiendl H, Meisel A. Diagnostics and Therapy of myasthenic syndromes. S2k-Guideline 2023. 2023.","DOI":"10.1007\/s42451-023-00568-6"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02856-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02856-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02856-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T13:23:42Z","timestamp":1716902622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02856-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2856"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02856-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,20]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C\u00e9cile van Steen and Sergio Iannazzo were employees of argenx BV, who manufacture efgartigimod, when the manuscript was completed. C\u00e9cile van Steen has since changed affiliation to Biogen Netherlands BV. Celico, Spaepen, Bodicoat and de Francesco have received research funding from argenx BV. Hagenacker has received research support from Biogen, Novartis GeneTherapies, Roche and Sanofi Genzyme, speakers and consultant honoraria from Biogen, Hormosan, Roche, Alexion, Novartis, Roche, Sanofi-Genzyme, Alnylam and Argenx. Sven G. Meuth received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer HealthCare, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Bundesinstitut f\u00fcr Risikobewertung (BfR), Deutsche Forschungsgemeinschaft (DFG), Else Kr\u00f6ner Fresenius Foundation, Gemeinsamer Bundesausschuss (G-BA), German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and by Alexion, Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Merck Serono, Novartis, ONO Pharma, Roche, and Teva. Tobias Ruck reports grants from German Ministry of Education, Science, Research and Technology; grants and personal fees from Sanofi-Genzyme; personal fees from Biogen and Novartis; personal fees and non-financial support from Merck Serono; personal fees from Roche, Teva, Alexion, argenx BV, UCB, and BMS. A Gordon Smith has received research support from Alexion, argenx BV, Janssen, Seismic, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors, therefore IRB approval was not required. In this indirect treatment comparison, no real-life patients were included and IRB approval was therefore not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}